Showing results (111-120 of 194) with videos related to

Sort By:
Pageof 20
ESMO Open|November 7, 2017
Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinomaPhilippe Merle, Philippe Camus, Armand Abergel, et al.
European Journal of Gastroenterology & Hepatology|December 23, 2017
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO studyDominique Roulot, Vincent Thibault, Claire Laforest, et al.
Plos One|December 17, 2015
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyFrédégonde About, Tiphaine Oudot-Mellakh, Jonathan Niay, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Hepatology (Baltimore, Md.)|October 20, 2012
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trialMark S Sulkowski, Fred Poordad, Michael P Manns, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
The American Journal of Clinical Nutrition|January 13, 2012
Helicobacter pylori serologic status has no influence on the association between fucosyltransferase 2 polymorphism (FUT2 461 G->A) and vitamin B-12 in Europe and West AfricaAbderrahim Oussalah, Cyril Besseau, Céline Chery, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Clinics and Research in Hepatology and Gastroenterology|April 11, 2022
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic responseJessica Azzi, Céline Dorival, Carole Cagnot, et al.
Pageof 20